Essilor’s revenue rose to CA$1.59 million in the third quarter of 2014, a 14.5% increase over the same period last year.

In North America, sales increased by 7.1%, as the result of a communication strategy in the United States to promote its brands Varilux, Crizal, Transitions, and Xperio among independent optometrists.

The company reported an 11.2% increase in emerging markets, which counted for 22% of consolidated sales. Recent acquisitions, such as Xiamen Yarui Optical, Costa Inc., coastal.com and Transitions Optical, also contributed to increased growth.

For further information: http://www.essilor.com/fr/Press/News/Pages/Informationfinancieredu3emetrimestre2014.aspx

Despite a good quarter for the company in general (sales of US$18.5 billion, up by 5.1% over last year), Johnson & Johnson reported a drop in eye care product sales in the third quarter of 2014.

Johnson & Johnson gave competitive pricing as a reason for the drop in eye care product sales of 5.9%, compared with 2013. These sales were CA$786 million in the third quarter of 2014. The drop was dramatic in the United States (-12.5%) and less harsh in other markets (-2.3%).

For further information: http://www.jnj.com/news/all/Johnson-and-Johnson-Reports-2014-Third-Quarter-Results

Quebec-based Valeant Pharmaceuticals, owner of Bausch + Lomb, among others, recorded its second best quarterly results since it was founded in 1960.

The company reported C$2.36 billion in revenue for its third quarter in 2014, compared with C$1.69 billion for the same period in 2013. But profits were even more dramatic: net income was C$309.5 million in the third quarter of 2014, compared with a loss of C$1.09 billion a year earlier.

Valeant’s revenues in contact lenses rose by 82% in a year. In total, Bausch + Lomb organic growth was 12%.

Valeant directly alluded to Allergan’s attacks, saying that these outstanding results illustrate the strength of its business model. Since Valeant first started trying to acquire Allergan, the latter has continually publicly criticized Valeant’s business model. Prior to Valeant releasing its results, Allergan even posted online a 30-page document, describing the points on which investors should evaluate the pharmaceutical company’s performance. The document has since been withdrawn.

Valeant CEO Michael Pearson stated in a conference call that they “have shown through performance that all the allegations made by Allergan are just wrong,” according to La Presse. In the same breath, he said he was ready to sit down with Allergan executives and increase the hostile bid offer, presently evaluated at about C$50 billion.

Sources: http://ir.valeant.com/investor-relations/news-releases/news-release-details/2014/Valeant-Pharmaceuticals-Reports-Third-Quarter-2014-Financial-Results/default.aspx

http://affaires.lapresse.ca/resultats-financiers/201410/20/01-4810785-valeant-disposee-a-modifier-son-offre-sur-allergan.php

http://www.visionmonday.com/business/financial/article/valeant-pharmaceuticals-reports-revenue-increase-for-q3-1/